– $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway,
ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the third quarter of 2025.
Corporate Highlights from 3Q 2025
Announced second partner order for FemBloc in Europe
Announced FDA IDE approval to continue enrollment in final phase of the FINALE pivotal trial for FemBloc
Announced a definitive agreement for the issuance of $12 million in secured convertible notes and accompanying warrants for total potential funding of $58 million, if all warrants are exercised for cash
Announced the initiation of post-market surveillance study for FemBloc in Europe
Announced partnership with Kebomed, a leading European distributor of medical devices and equipment, to commercialize FemBloc in France and the Benelux region (the Netherlands, Belgium and Luxembourg)
Announced partnership with Medical Electronic Systems LLC to provide FemSperm™ Analysis Kit for use with FemaSeed®
Announced FemSperm Setup and Preparation Kits, designed to fully enable gynecologists to perform FemaSeed Intratubal Insemination
Announced New Zealand regulatory approval of FemBloc
Announced underwritten public offering with gross proceeds of $8 million
Announced United Kingdom regulatory approval of FemBloc
"Our third quarter marked several pivotal milestones for Femasys as we advanced on multiple fronts, securing key regulatory approvals, strengthening our balance sheet through new financing, and expanding global partnerships for FemBloc, all reinforcing our commitment to delivering innovative solutions for women's health," said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys. "Regulatory approvals of the complete FemBloc System in the U.K. and New Zealand significantly expand access to this revolutionary, non-surgical permanent birth control option across Europe and the Asia-Pacific region. With initial commercial orders received from our distribution partners in Spain and France, we are building early momentum as we pursue additional country approvals. At the same time, we continue to advance toward U.S. approval of FemBloc, following the FDA's recent IDE approval to initiate the final pivotal trial phase required for regulatory approval."
Financial Results for Quarter Ended September 30, 2025
Sales increased by $174,486, or 31.4%, to $729,394 for the three months of 2025, compared to $554,908 for the three months of 2024 primarily due to sales of FemBloc.
Research and development expenses decreased by $921,219, or 40.0%, to $1,382,022 for the three months of 2025 compared to $2,303,241 for the three months of 2024 primarily due to commercialization of development products into inventory and reduced compensation costs, clinical costs and professional fees.
Net loss was $4,194,821, or ($0.10) per basic and diluted share attributable to common stockholders, for the three-month period ended September 30, 2025, compared to a net loss of $5,408,860, or ($0.24) per basic and diluted share attributable to common stockholders, for the three-month period ended September 30, 2024.
Cash and cash equivalents as of September 30, 2025, was approximately $4.6 million and the Company had an accumulated deficit of approximately $141.9 million. The Company expects, based on its current operating plan, our current cash and cash equivalents, which includes proceeds from our recent financing, will be sufficient to fund its ongoing operations into September 2026.
Financial Results for Nine Months Ended September 30, 2025
Sales increased by $432,394, or 41.3%, to $1,479,926 for the nine months of 2025, compared to $1,047,532 for the nine months of 2024 due to sales of FemBloc and FemVue.
Research and development expenses decreased by $284,924, or 4.7%, to $5,764,923 for the nine months of 2025 compared to $6,049,847 for the nine months of 2024 primarily due to commercialization of development products into inventory, reduced clinical costs and professional fees, partially offset by increased regulatory costs.
Net loss was $14,677,582, or ($0.46) per basic and diluted share attributable to common stockholders, for the nine-month period ended September 30, 2025, compared to a net loss of $13,692,944, or ($0.62) per basic and diluted share attributable to common stockholders, for the same period ended September 30, 2024.
For more information, please refer to the Company's Form 10-Q filed November 14, 2025, which can be accessed on the SEC website.
FEMASYS INC.
Condensed Balance Sheets
(unaudited)
Assets
September 30, 2025
December 31, 2024
Current assets:
Cash and cash equivalents
$
4,569,038
3,451,761
Accounts receivable, net
572,199
488,373
Inventory
5,783,974
3,046,323
Prepaid and other current assets
1,321,689
1,035,993
Total current assets
12,246,900
8,022,450
Property and equipment, at cost:
Leasehold improvements
1,238,886
1,238,886
Office equipment
78,155
60,921
Furniture and fixtures
417,876
417,876
Machinery and equipment
3,283,672
2,856,740
Construction in progress
687,462
762,445
5,706,051
5,336,868
Less accumulated depreciation
(3,956,987
)
(3,740,769
)
Net property and equipment
1,749,064
1,596,099
Long-term assets:
Lease right-of-use assets, net
1,419,345
1,805,543
Intangible assets, net of accumulated amortization
130,041
65,918
Other long-term assets
744,803
954,992
Total long-term assets
2,294,189
2,826,453
Total assets
$
16,290,153
12,445,002
(continued)
